248. グルコーストランスポーター1欠損症 [臨床試験数:30,薬物数:9(DrugBank:1),標的遺伝子数:0,標的パスウェイ数:0]

Searched query = "Glucose transporter type 1 deficiency", "GLUT1 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
17 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03773770December 27, 201910/12/2018Expanded Access to TriheptanoinAn Open-label Intermediate-size Treatment Protocol for the Urgent Treatment of Seriously Ill Patients With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) With Triheptanoin (UX007)Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Drug: TriheptanoinUltragenyx Pharmaceutical IncNULLAvailableN/AN/AAllNULL
2NCT03301532June 5, 201829/8/2017Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1DCompatibility of Triheptanoin (C7) With the Ketogenic Diet in Patients Diagnosed With Glucose Transporter Type 1 DeficiencyGLUT1DS1Drug: TriheptanoinUniversity of Texas Southwestern Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruiting30 Months35 YearsAll15Phase 2United States
3NCT03181399April 18, 201825/4/2017Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D)GLUT1DS1;Epilepsy;Glut1 Deficiency Syndrome 1, Autosomal Recessive;Glucose Metabolism Disorders;Glucose Transport Defect;Glucose Transporter Type 1 Deficiency Syndrome;Glucose Transporter Protein Type 1 Deficiency SyndromeDrug: TriheptanoinUniversity of Texas Southwestern Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruiting24 Months35 YearsAll45Phase 2United States
4EUCTR2013-003771-35-DK07/06/201711/04/2017A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome Glucose Transporter Type 1 deficiency syndrome
MedDRA version: 20.0Level: LLTClassification code 10061032Term: Carbohydrate transport disorderSystem Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Triheptanoin
Product Code: UX007
INN or Proposed INN: Not available
Other descriptive name: TRIHEPTANOIN
Ultragenyx Pharmaceutical IncNULLNot RecruitingFemale: yes
Male: yes
40Phase 2France;United States;Hungary;Spain;Australia;Denmark;Israel;Italy;United Kingdom
5NCT03041363March 29, 201731/1/2017Treatment Development of Triheptanoin (G1D)Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose TrialEpilepsy;GLUT1DS1;Glut1 Deficiency Syndrome 1, Autosomal Recessive;Glucose Metabolism Disorders;Glucose Transport Defect;Glucose Transporter Type 1 Deficiency Syndrome;Glucose Transporter Protein Type 1 Deficiency SyndromeDrug: TriheptanoinUniversity of Texas Southwestern Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruiting2 Years35 YearsAll36Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02968953March 17, 201716/11/2016Treatment With UX007 for a Single Patient With GLUT1 Deficiency SyndromeTreatment With UX007 (Triheptanoin) for a Single Patient (ERS) With Glucose Transporter 1 (GLUT1) Deficiency SyndromeGlucose Transporter 1 Deficiency SyndromeDrug: TriheptanoinJerry Vockley, MD, PhDUltragenyx Pharmaceutical IncNo longer available3 YearsN/AFemaleUnited States
7EUCTR2013-003771-35-HU13/04/201610/08/2015A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome Glucose Transporter Type 1 deficiency syndrome
MedDRA version: 18.1Level: HLGTClassification code 10039911Term: Seizures (incl subtypes)System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Triheptanoin
Product Code: UX007
INN or Proposed INN: Not available
Other descriptive name: TRIHEPTANOIN
Ultragenyx Pharmaceutical IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40France;United States;Hungary;Spain;Denmark;Australia;Israel;Italy;United Kingdom
8NCT02021526December 201512/12/2013Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)Treatment Development of Triheptanoin for Glucose Transporter Type I DeficiencyGlucose Transporter Type 1 Deficiency Syndrome;Glut1 Deficiency SyndromeDrug: TriheptanoinJuan PascualNULLWithdrawn30 Months55 YearsAll0Phase 1/Phase 2United States
9EUCTR2013-003771-35-ES19/11/201510/08/2015A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome Glucose Transporter Type 1 deficiency syndrome
MedDRA version: 18.0Level: HLGTClassification code 10039911Term: Seizures (incl subtypes)System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Triheptanoin / Triheptanoina
Product Code: UX007
INN or Proposed INN: Not available
Other descriptive name: TRIHEPTANOIN
Ultragenyx Pharmaceutical IncNULLNot RecruitingFemale: yes
Male: yes
40Phase 2France;United States;Hungary;Spain;Denmark;Italy;United Kingdom
10NCT02000960April 201427/11/2013Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency SyndromeA Controlled N-of-1 Before-and-after Study to Determine Safety and Efficacy Triheptanoin in Patients With Glucose Transporter 1 Deficiency SyndromeGlucose Transporter Type 1 Deficiency SyndromeDrug: TriheptanoinUniversity of British ColumbiaUltragenyx Pharmaceutical IncActive, not recruiting1 Year18 YearsBoth3Phase 2Canada
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01993186February 28, 201431/10/2013Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency SyndromeGlucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Drug: UX007;Drug: PlaceboUltragenyx Pharmaceutical IncNULLCompleted1 Year100 YearsAll36Phase 2United States;Australia;France;Israel;Italy;Spain;United Kingdom;Hungary
12EUCTR2013-003771-35-IT11/02/201411/12/2013A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome Glucose Transporter Type 1 deficiency syndrome
MedDRA version: 14.1Level: HLGTClassification code 10039911Term: Seizures (incl subtypes)System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Triheptanoin
Product Code: UX007
INN or Proposed INN: Not available
Other descriptive name: TRIHEPTANOIN
Ultragenyx Pharmaceutical IncNULLNot RecruitingFemale: yes
Male: yes
80Phase 2France;United States;Hungary;Spain;Denmark;Netherlands;United Kingdom;Italy
13NCT02036853January 201413/1/2014An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency SyndromeAn Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS)Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)Drug: TriheptanoinAdrian LacyUltragenyx Pharmaceutical IncRecruiting1 Year50 YearsAll50Phase 2United States
14NCT02014883December 20133/12/2013Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DSPhase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DSGlut1 Deficiency SyndromeDrug: GLUT1 DSInstitut National de la Santé Et de la Recherche Médicale, FranceUltragenyx Pharmaceutical IncRecruiting3 YearsN/ABoth20Phase 2France
15NCT02018302October 201311/12/2013Post Study Continuation of C7 for G1DPost Study Continuation of C7 for G1DGlut1 Deficiency Syndrome;Glucose Transporter Type 1 Deficiency SyndromeDrug: TriheptanoinJuan PascualNULLNo longer available1 Month28 YearsAllUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02018315January 201211/12/2013Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)Clinical Trial of Citric Acid Cycle Stimulation in Energy-deficiency States: Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) (NMTUT 2010B)Glucose Transporter Type 1 Deficiency Syndrome;GLUT1 Deficiency SyndromeDrug: TriheptanoinJuan PascualNULLCompleted1 Month20 YearsAll14Phase 1United States
17EUCTR2013-003771-35-FR17/06/2015A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome Glucose Transporter Type 1 deficiency syndrome
MedDRA version: 18.0Level: HLGTClassification code 10039911Term: Seizures (incl subtypes)System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Triheptanoin
Product Code: UX007
INN or Proposed INN: Not available
Other descriptive name: TRIHEPTANOIN
Ultragenyx Pharmaceutical IncNULLNAFemale: yes
Male: yes
80Phase 2United States;France;Hungary;Spain;Denmark;Italy;United Kingdom